PLX · CIK 0001006281 · FY2025 live · 2025-12-31
Protalix BioTherapeutics, Inc.
View as
Model
Classic Z
FY2025
−4.69
Zone
Distress
Prior
—
Market DD
—
1y PD
—
−4.69
Z″ −11.01
Score −4.69 · distress below 1.80, grey to 2.99, safe at 3.00 and above.
Classic Z factor contributions
X1 Working capital / assets
Short-term liquidity versus the size of the balance sheet.
0.491.2 × = 0.59X2 Retained earnings / assets
Cushion from years of profits. Share buybacks can push this negative at otherwise healthy firms.
−4.681.4 × = −6.55X3 EBIT / assets
Operating return on assets. Highest weight in the original model.
−0.073.3 × = −0.22X4 Book equity / liabilities
Book equity versus the liability stack. Mega-caps often look greyer here than they would if X4 used market cap.
1.410.6 × = 0.85X5 Sales / assets
Asset turnover — how much revenue the asset base supports.
0.641 × = 0.64
Five-year path
Need two annual 10-Ks to draw a path. The desk will pull this issuer’s filings rather than invent a series.
Overview
rule-v1
Protalix BioTherapeutics, Inc. is on classic Z at −4.69 (distress) for FY2025, from an SEC 10-K. Retained earnings / assets is the line that sets the print. This is the first live year on the desk. No market tape loaded. Classic Z was fit on manufacturers; buybacks can send retained earnings negative at otherwise healthy issuers, and X4 is book equity, not market cap.
Book screen Distress; market PD —. Tape not priced — not a single default call.
Market DD · naive Merton
No market tape yet.
Pull a year of closes (Yahoo, Nasdaq if Yahoo is limited) and size equity from Nasdaq cap or EDGAR shares. Distance-to-default and 1-year PD stay blank until then.
Sector peers
Closest Classic Z scores · 31st percentile in Healthcare.
- RCKTDistressROCKET PHARMACEUTICALS, INC.−4.71
- TLRYDistressTilray Brands, Inc.−4.72
- CTMXDistressCytomX Therapeutics, Inc.−4.66
- PRMEDistressPrime Medicine, Inc.−4.79
- QCLSDistressQ/C TECHNOLOGIES, INC.−4.57
- OMERDistressOMEROS CORP−4.83
- ZNTLDistressZentalis Pharmaceuticals, Inc.−4.84
- INBXDistressInhibrx Biosciences, Inc.−4.54
KPI widgets
Current assets
$67M
Total assets
$82M
Current liabilities
$27M
Total liabilities
$34M
Working capital
$40M
Retained earnings
−$385M
EBIT
−$6M
Total sales
$53M
Book equity
$48M
Accession 0001104659-26-029858. Live rank is the latest 10-K on EDGAR (FY2025, period 2025-12-31). Classic Z is the live score. View as does not rewrite the live rank. X4 is book equity. Pulled 12 Sept 2026.